Synergistic antitumor effect of a human papillomavirus DNA vaccine harboring E6E7 fusion gene and vascular endothelial growth factor receptor 2 gene

Microbiology and Immunology

Volumn 60, Issue 9, 2016, Pages 626-633

  Gao, Jie ^a   Fan, Lei ^b   Ma, Wei ^a   Xiao, Huan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Aerospace 731 Hospital   (China)

Author keywords

cervical cancer; DNA vaccine; HPV; VEGFR2

Indexed keywords

DNA VACCINE; PLASMID DNA; PROTEIN E6; PROTEIN E7; VASCULOTROPIN RECEPTOR 2; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MODEL; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; E6E7 GENE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FUSION GENE; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PAPILLOMAVIRUS INFECTION; PROTEIN EXPRESSION; READING FRAME; SOLID TUMOR; VACCINE PRODUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 GENE;

EID: 84988490288     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/1348-0421.12408     Document Type: Article

References (19)

1. Wigle J., Fontenot H.B., Zimet G.D. (2016) Global delivery of human papillomavirus vaccines. Pediatr Clin North Am 63: 81–95.
2. Ding S., Qian S.Y., Zhang Y., Wu W., Lu G., Lu Y., Feng X., Li L., Shen P. (2015) Establishment of immunoassay for detecting HPV16 E6 and E7 RNA. Sci Rep 5: 13686.
3. de Oliveira L.M., Morale M.G., Chaves A.A., Cavalher A.M., Lopes A.S., Diniz Mde O., Schanoski A.S., de Melo RL., Ferreira L.C., de Oliveira M.L., Demasi M., Ho P.L. (2015) Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine. PLoS ONE 10: e0138686.
4. Kumar S., Biswas M., Jose T. (2015) HPV vaccine: Current status and future directions. Med J Armed Forces India 71: 171–7.
5. Li L. Saade F. Petrovsky N. (2012) The future of human DNA vaccines. J Biotechnol 162: 171–82.
6. Lin K., Roosinovich E., Ma B., Hung C.F., Wu T.C. (2010) Therapeutic HPV DNA vaccines. Immunol Res 47: 86–112.
7. Saade F., Petrovsky N. (2012) Technologies for enhanced efficacy of DNA vaccines. Exp Rev Vaccines 11: 189–209.
8. Choi H.S., Lee K., Kim M.K., Lee K.M., Shin Y.C., Cho S.G., Ko S.G. (2016) DSGOST inhibits tumor growth by blocking VEGF/VEGFR2-activated angiogenesis. Oncotarget 7:21775–85.
9. Yan H.X., Cheng P., Wei H.Y., Shen G.B., Fu L.X., Ni J., Wu Y., Wei Y.Q. (2013) Active immunotherapy for mouse breast cancer with irradiated whole-cell vaccine expressing VEGFR2. Oncol Rep 29:1510–6.
10. Coleman H.N., Greenfield W.W., Stratton SL., Vaughn R., Kieber A., Moerman-Herzog A.M., Spencer H.J., Hitt W.C., Quick C.M., Hutchins L.F., Mackintosh S.G., Edmondson R.D., Erickson S.W., Nakagawa M. (2016) Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination. Cancer Immunol Immunother 65:563–73.
11. Rodrigues L.C., de Gois Speck N.M., de Azevedo Focchi G.R. Schmidt M.A., Marques R.M. Lascasas Ribalta J.C. (2016) Immunoexpression of HPV 16/18 E6 and E7 oncoproteins in high-grade cervical squamous intraepithelial lesions in HIV-positive women. Genet Mol Res DOI: 10.4238/gmr.15017220.
12. Wong K.K., Li W.A., Mooney D.J., Dranoff G. (2016) Advances in therapeutic cancer vaccines. Adv Immunol 130:191–249.
13. Strauss J., Madan R.A. (2016) Therapeutic vaccines for prostate cancer: Recent advances and future directions. Expert Rev Vaccines 7:1–8.
14. Tan S., de Vries E.G., van der Zee A.G., de Jong S. (2012) Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. Curr Cancer Drug Targets 12:170–84.
15. Villarreal D.O., Talbott K.T., Choo D.K., Shedlock D.J., Weiner D.B. (2013) Synthetic DNA vaccine strategies against persistent viral infections. Exp Rev Vaccines 12:537–54.
16. Wang Z., Dabrosin C., Yin X., Fuster M.M., Arreola A., Rathmell W.K., Generali D., Nagaraju G.P., El-Rayes B., Ribatti D., Chen Y.C., Honoki K., Fujii H., Georgakilas A.G., Nowsheen S., Amedei A., Niccolai E., Amin A., Ashraf S.S., Helferich B., Yang X., Guha G., Bhakta D., Ciriolo M.R., Aquilano K., Chen S., Halicka D., Mohammed S.I., Azmi A.S., Bilsland A., Keith W.N., Jensen L.D. (2015) Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 35: S224–43.
17. Jia S., Cai J. (2016) Update on biomarkers in development of anti-angiogenic drugs in gastric cancer. Anticancer Res 36: 1111–8.
18. Xing Y., Tu J., Zheng L., Guo L., Xi T. (2015) Anti-angiogenic effect of tanshinone IIA involves inhibition of the VEGF/VEGFR2 pathway in vascular endothelial cells. Oncol Rep 33: 163–70.
19. Chen R., Wang S., Yao Y., Zhou Y., Zhang C., Fang J., Zhang D., Zhang L., Pan J. (2015) Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide. Oncol Rep 33: 2269–76.